Small bowel capsule endoscopy in obscure gastrointestinal bleeding: normalcy is not reassuring

Area of Science:

• Gastroenterology
• Diagnostic Endoscopy
• Internal Medicine

Background:

• Small bowel capsule endoscopy (SBCE) is a key tool for diagnosing obscure gastrointestinal bleeding (OGIB).
• The long-term implications of a negative SBCE, including rebleeding risk, require further investigation.

Purpose of the Study:

• To evaluate outcomes in patients with OGIB and negative SBCE results.
• To assess follow-up duration, further diagnostic procedures, diagnosis rates, and rebleeding incidence.
• To identify factors associated with rebleeding after a negative SBCE.

Main Methods:

• Retrospective analysis of 256 patients undergoing SBCE for OGIB (April 2006-December 2011).
• Included 68 patients with negative SBCE results in a nested case-control analysis.
• Collected data on follow-up, rebleeding events, and patient demographics/comorbidities.

Main Results:

• Mean follow-up was 32 months for 68 patients (52 years old, 61.8% female).
• Rebleeding occurred in 16 patients (23.5%), with a mean onset of 15 months post-SBCE.
• Male sex was significantly associated with a higher rebleeding incidence (P=0.004).

Conclusions:

• Approximately 25% of OGIB patients with negative SBCE experience rebleeding, particularly men.
• A negative SBCE is not definitive, and rebleeding often occurs within two years.
• Regular medical surveillance is recommended for at least two years after a negative SBCE in OGIB patients.